ENZARAD Phase 3 Trial: Enzalutamide Plus ADT and Radiotherapy in High-Risk Prostate Cancer

ENZARAD Phase 3 Trial: Enzalutamide Plus ADT and Radiotherapy in High-Risk Prostate Cancer

For patients with high-risk localized or locally advanced prostate cancer, radiotherapy combined with long-term androgen deprivation therapy (ADT) remains an established treatment approach. However, whether intensifying androgen receptor inhibition with newer agents can further improve outcomes in this setting has been an important area of clinical research.

Enzalutamide, an androgen receptor pathway inhibitor, has demonstrated survival benefits in several advanced prostate cancer settings. Its role alongside definitive radiotherapy and long-term ADT in high-risk nonmetastatic disease has been less clear.

The phase III ENZARAD trial investigated whether replacing a first-generation nonsteroidal antiandrogen with enzalutamide could improve metastasis-free survival in patients receiving definitive radiotherapy and ADT.

The results of the international phase III ENZARAD (ANZUP 1303) trial were published in the Journal of Clinical Oncology on October 24, 2026, under the title: “ENZARAD (ANZUP 1303): Phase III Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer.”

The study was authored by Scott Williams, Christopher J. Sweeney, Hayley Thomas, Blossom Mak, Alison Zhang, Tee Sin Lim, Chakiath Jose, Jarad Martin, Nitya Patanjali, David Pryor, Phuong Tran, Stephen Mangar, Alina M. Mihai, Carys Thomas, Simon Gampenrieder, Sonia Yip, Leanna Cheung, Sandra Lee, Annabelle Goodwin, Annette Haworth, Anna Walsh, Paul J. Kelly, Simon Hughes, Andrew Martin, Ray McDermott, Martin Stockler, Ian D. Davis, and Paul L. Nguyen.

ENZARAD was an international, randomized, open-label phase III trial conducted across 63 centers. Between March 2014 and June 2018, investigators enrolled 802 patients with high-risk localized or locally advanced prostate adenocarcinoma, including patients with regional lymph node involvement but no distant metastases on conventional imaging.

The median age was 71 years. At baseline, 54% of participants had Gleason scores of 9–10, 47% had T3–4 disease, and 11% had clinically positive pelvic lymph nodes. The median prostate-specific antigen (PSA) level was 14 ng/mL.

Study Design and Treatment

Participants were randomly assigned in a 1:1 ratio to two treatment groups:

  • Enzalutamide group (n=401): Enzalutamide 160 mg once daily for 96 weeks, combined with long-term ADT and definitive radiotherapy.
  • Control group (n=401): A first-generation nonsteroidal antiandrogen (bicalutamide, nilutamide, or flutamide) for 24 weeks, combined with the same long-term ADT and radiotherapy approach.

All participants were scheduled to receive approximately 24 months of ADT with a luteinizing hormone-releasing hormone analogue. Definitive radiotherapy was directed to the prostate, with pelvic lymph node irradiation required for patients with cN1 disease and optional for those with cN0 disease.

The primary endpoint was metastasis-free survival assessed using conventional imaging (MFS-CI), defined as the time from randomization to distant metastasis or death from any cause. Secondary endpoints included overall survival (OS), prostate cancer-specific survival, PSA progression-free survival (PSA-PFS), time to subsequent hormonal therapy, time to castration-resistant prostate cancer, and safety.

Primary Results: No Significant Improvement in Metastasis-Free Survival

After a median follow-up of 92 months, the primary analysis included 207 metastasis-free survival events, with 98 events in the enzalutamide group and 109 in the control group.

At 8 years, MFS-CI rates were:

  • Enzalutamide: 74%
  • Control: 72%
  • Hazard ratio: 0.88 (95% CI, 0.67–1.15; P=0.34)

The difference was not statistically significant, indicating that replacing a first-generation nonsteroidal antiandrogen with 24 months of enzalutamide did not significantly improve the primary endpoint in the overall study population.

Among the reported events, distant metastases occurred in 46 patients receiving enzalutamide and 50 patients in the control group. Death before documented metastasis occurred in 52 and 59 patients, respectively.

ENZARAD Phase 3 Trial: Enzalutamide Plus ADT and Radiotherapy in High-Risk Prostate Cancer

Overall Survival and Secondary Outcomes

Overall survival results were consistent with the primary analysis. At 8 years, OS was 83% with enzalutamide compared with 80% in the control group (HR 0.87; 95% CI, 0.63–1.20).

A total of 146 deaths were reported, including 69 in the enzalutamide group and 77 in the control group. Prostate cancer-specific survival at 8 years was also similar between groups, at 97% and 96%, respectively (HR 0.90; 95% CI, 0.41–1.97).

For PSA progression-free survival, a modest difference favoring enzalutamide was observed:

  • 8-year PSA-PFS: 67% with enzalutamide versus 62% with control.
  • HR: 0.78 (95% CI, 0.61–0.99; P=0.044).

Although this secondary endpoint favored enzalutamide, no statistically significant improvement in metastasis-free or overall survival was observed in the overall study population.

Subgroup Analysis: Possible Benefit in Patients Planned for Pelvic Nodal Radiotherapy

One of the notable findings emerged from the prespecified subgroup analysis examining patients for whom pelvic nodal radiotherapy was planned. Among 324 patients with planned pelvic nodal irradiation, enzalutamide was associated with more favorable metastasis-free survival (HR 0.47; 95% CI, 0.29–0.76). In contrast, among patients without planned pelvic nodal irradiation, the HR was 1.25 (95% CI, 0.89–1.76).

The interaction between treatment assignment and planned pelvic irradiation was statistically significant after adjustment for multiple comparisons (adjusted P=0.004). A possible benefit was also observed in the cN1 subgroup, which included 88 patients (HR 0.43; 95% CI, 0.20–0.92).

Further exploratory analyses showed that among patients with cN0 disease who were planned to receive pelvic nodal radiotherapy, 5-year MFS-CI was 91% with enzalutamide versus 81% with control (HR 0.49; 95% CI, 0.27–0.89). For patients with cN1 disease, corresponding 5-year rates were 85% and 77%, respectively.

However, these subgroup findings require cautious interpretation. Although planned pelvic irradiation was a prespecified subgroup, treating clinicians decided whether to include pelvic lymph nodes in the radiation field before randomization to enzalutamide or control treatment; the radiotherapy field itself was not randomized.

Differences in baseline risk and treatment selection may therefore have influenced the observed results. The investigators considered these findings hypothesis-generating and emphasized the need for prospective validation before identifying patients who may benefit from this treatment approach.

Safety and Treatment Tolerability

Adverse events were common in both treatment groups. Any-grade adverse events occurred in 99% of patients receiving enzalutamide and 98% of those receiving a first-generation nonsteroidal antiandrogen.

Grade 3–5 adverse events were reported in 46% of patients in each group, corresponding to 185 participants per arm. The safety profile was generally consistent with the known toxicities of the treatments used. Fatigue and nausea were more frequent with enzalutamide, whereas elevations in liver transaminases were less frequent.

Fatigue was reported in 88% of patients receiving enzalutamide compared with 80% in the control group. Overall late radiotherapy-associated morbidity was similar between groups, although grade 3 or higher bladder and bowel complications were numerically more frequent with enzalutamide. These occurred in 12 versus 6 patients for bladder morbidity and 13 versus 4 patients for bowel morbidity, respectively.

Treatment completion rates were comparable, at 85% with enzalutamide and 86% with control. Adverse events were associated with treatment discontinuation in 27 patients assigned to enzalutamide and nine assigned to the control treatment.

Clinical Implications and Future Directions

The ENZARAD findings provide long-term evidence regarding androgen receptor pathway intensification in patients receiving definitive radiotherapy and ADT for high-risk localized or locally advanced prostate cancer. Importantly, the results differ from those of STAMPEDE, which demonstrated improved metastasis-free and overall survival with abiraterone-based treatment intensification in a higher-risk nonmetastatic population.

The ENZARAD investigators highlighted important differences between the studies, particularly in baseline disease characteristics. Compared with ENZARAD, STAMPEDE included higher proportions of patients with T3–4 disease and clinically positive lymph nodes, as well as higher baseline PSA levels.

These differences, alongside the distinct treatment regimens evaluated, limit direct comparisons between the trials. Another consideration is that ENZARAD relied on conventional imaging for disease staging and assessment of metastasis-free survival. The study did not establish whether baseline PSMA PET imaging could identify patients more likely to benefit from enzalutamide intensification.

The investigators also acknowledged the open-label design and the use of PSA- or clinically triggered follow-up imaging rather than imaging at fixed intervals as study limitations. Further research incorporating PSMA PET, molecular profiling, and prospective validation of the subgroup findings may help identify patients who could benefit from androgen receptor pathway intensification.

Takeaway

The phase III ENZARAD trial found that 24 months of enzalutamide, compared with 6 months of a first-generation nonsteroidal antiandrogen, did not significantly improve metastasis-free or overall survival when combined with definitive radiotherapy and approximately 24 months of ADT in the overall population of patients with high-risk localized or locally advanced prostate cancer.

Although a possible metastasis-free survival benefit was observed among patients planned for pelvic nodal radiotherapy, this finding requires further validation and does not establish a predictive subgroup. The results highlight the importance of risk stratification when considering systemic treatment intensification and do not support routinely replacing a first-generation nonsteroidal antiandrogen with enzalutamide in the overall ENZARAD-eligible population.

The full article is available in Journal of Clinical Oncology.

Sona Karamyan
Fact checked by Sona Karamyan MD, Medical Oncologist
Amalya Sargsyan
Medically reviewed by Amalya Sargsyan MD, Medical Oncologist